TL;DR
This study suggests that montelukast (MTK), commonly used for asthma, may significantly reduce the incidence of delirium and 90-day mortality in critically ill asthma patients. The findings indicate that MTK's anti-inflammatory properties could be a novel therapeutic avenue for delirium, with its effect on mortality partially mediated by delirium reduction.
What Problem Does This Paper Address?
Critically ill patients, particularly those with asthma, are at high risk of developing delirium, a serious condition characterized by attention disturbances and altered consciousness. Delirium is associated with increased mortality and poor long-term outcomes, yet effective treatments remain elusive. While the exact mechanisms of delirium are complex, neuroinflammation and oxidative stress are implicated. Montelukast (MTK), a potent antagonist of cysteinyl leukotriene receptor 1 (CysLTR1), is known for its anti-inflammatory and antioxidant properties and has shown promise in treating other neuropsychiatric disorders. This paper investigates whether pre-intensive care unit (ICU) MTK use can mitigate delirium incidence and improve prognosis in critically ill asthma patients.
Methods
The researchers conducted a retrospective cohort study using the MIMIC-IV database, a large, publicly available critical care dataset. They identified 6344 asthma patients admitted to the ICU. To account for potential confounding factors, they employed propensity score matching (PSM) to create comparable exposure (pre-ICU MTK use) and control groups. Statistical analyses included logistic and Cox regression to assess the association between MTK exposure and delirium/mortality. To further validate their findings and explore the robustness of the results, they used E-value sensitivity analysis. Causal mediation analysis was also performed to determine if delirium reduction played a mediating role in the association between MTK and 90-day mortality. Subgroup analyses were conducted to identify specific patient populations where MTK's effects were more pronounced.
Datasets
The study utilized the MIMIC-IV database (version 2.2), a publicly available dataset containing de-identified health-related data associated with over 50,000 intensive care unit admissions from Beth Israel Deaconess Medical Center between 2008 and 2019.
Key Insights and Ideas
- MTK as a potential anti-delirium agent: The most striking insight is the potential of MTK, a drug primarily known for respiratory conditions, to impact neuropsychiatric outcomes like delirium in critically ill patients. This broadens its therapeutic scope.
- Delirium as a mediator of mortality: The study provides evidence that MTK's beneficial effect on 90-day mortality is, at least in part, achieved by reducing the incidence of delirium. This highlights delirium as a critical intermediate factor in the patient's overall prognosis.
- Myocardial Infarction as a key modulator: The interaction analysis revealed that the protective effect of MTK against delirium was significantly attenuated in patients with a history of myocardial infarction. This suggests that pre-existing cardiovascular conditions might influence MTK's efficacy in this context.
- Duration of MTK use matters: Longer-term use of MTK appeared to enhance its beneficial effects on delirium, suggesting a potential dose-response relationship (though dosage itself wasn't the primary variable).
Key Results
After propensity score matching, pre-ICU MTK use was significantly associated with:
- Reduced in-hospital delirium: An odds ratio (OR) of 0.705 (95% CI 0.497–0.999, p = 0.049).
- Reduced 90-day mortality: An OR of 0.554 (95% CI 0.366–0.840, p = 0.005).
The association was more significant in patients without myocardial infarction. Causal mediation analysis indicated that the reduction in delirium partially mediated the reduction in 90-day mortality (ACME: -0.053, 95% CI -0.0142 to 0.0002, p = 0.020), accounting for 8.2% of the total effect.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective and single-center design: This limits the generalizability of the findings and prevents definitive causal conclusions. Further prospective studies are needed.
- Data limitations: The MIMIC-IV database has limitations regarding the specificity of ICD codes for identifying asthma and the lack of detailed daily delirium status.
- Potential for unmeasured confounders: Despite PSM and regression adjustments, residual confounding cannot be entirely ruled out. E-values were used to assess robustness, but they are for reference.
- Pediatric population exclusion: The study excluded patients under 18, limiting generalizability to children, where MTK-related neuropsychiatric events have been more frequently reported.
Future work should focus on prospective, randomized controlled trials to establish causality. Investigating the specific mechanisms by which MTK impacts neuroinflammation, neuronal function, and cognitive impairment in delirium is also crucial. Further research into optimal MTK dosing and duration, especially in patients with comorbidities like myocardial infarction, is warranted.
Summary updated